Czech National Bank Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Czech National Bank grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 37,386 shares of the medical research company’s stock after purchasing an additional 2,107 shares during the quarter. Czech National Bank’s holdings in IQVIA were worth $7,347,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB grew its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Simplify Asset Management Inc. raised its stake in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Versor Investments LP purchased a new position in shares of IQVIA in the 3rd quarter worth about $1,328,000. JPMorgan Chase & Co. increased its holdings in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the last quarter. Finally, CIBC Asset Management Inc raised its position in IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after acquiring an additional 8,490 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $198.12 on Wednesday. The company’s fifty day moving average price is $201.43 and its 200-day moving average price is $221.61. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $35.96 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 2.05 and a beta of 1.48. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Wednesday, December 11th. Redburn Atlantic assumed coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Robert W. Baird lowered their price objective on IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.